Scalper1 News
Big biotech Gilead Sciences handily beat analysts’ Q2 estimates and raised its full-year guidance Tuesday afternoon, led by sales of its blockbuster hepatitis C drugs. Earnings, excluding one-time items, rose 33.5% over the year-earlier quarter to $3.15 a share, beating analysts’ consensus by 44 cents, according to Thomson Reuters. Revenue climbed 26% to $8.24 billion, some $800 million above the Street’s number. Gilead (GILD) duly Scalper1 News
Scalper1 News